Molecular and Serologic Diagnostic Technologies for SARS-CoV-2
Authors:
Halie M. Rando,
Christian Brueffer,
Ronan Lordan,
Anna Ada Dattoli,
David Manheim,
Jesse G. Meyer,
Ariel I. Mundo,
Dimitri Perrin,
David Mai,
Nils Wellhausen,
COVID-19 Review Consortium,
Anthony Gitter,
Casey S. Greene
Abstract:
The COVID-19 pandemic has presented many challenges that have spurred biotechnological research to address specific problems. Diagnostics is one area where biotechnology has been critical. Diagnostic tests play a vital role in managing a viral threat by facilitating the detection of infected and/or recovered individuals. From the perspective of what information is provided, these tests fall into t…
▽ More
The COVID-19 pandemic has presented many challenges that have spurred biotechnological research to address specific problems. Diagnostics is one area where biotechnology has been critical. Diagnostic tests play a vital role in managing a viral threat by facilitating the detection of infected and/or recovered individuals. From the perspective of what information is provided, these tests fall into two major categories, molecular and serological. Molecular diagnostic techniques assay whether a virus is present in a biological sample, thus making it possible to identify individuals who are currently infected. Additionally, when the immune system is exposed to a virus, it responds by producing antibodies specific to the virus. Serological tests make it possible to identify individuals who have mounted an immune response to a virus of interest and therefore facilitate the identification of individuals who have previously encountered the virus. These two categories of tests provide different perspectives valuable to understanding the spread of SARS-CoV-2. Within these categories, different biotechnological approaches offer specific advantages and disadvantages. Here we review the categories of tests developed for the detection of the SARS-CoV-2 virus or antibodies against SARS-CoV-2 and discuss the role of diagnostics in the COVID-19 pandemic.
△ Less
Submitted 28 April, 2022; v1 submitted 26 April, 2022;
originally announced April 2022.
Identification and Development of Therapeutics for COVID-19
Authors:
Halie M. Rando,
Nils Wellhausen,
Soumita Ghosh,
Alexandra J. Lee,
Anna Ada Dattoli,
Fengling Hu,
James Brian Byrd,
Diane N. Rafizadeh,
Ronan Lordan,
Yanjun Qi,
Yuchen Sun,
Christian Brueffer,
Jeffrey M. Field,
Marouen Ben Guebila,
Nafisa M. Jadavji,
Ashwin N. Skelly,
Bharath Ramsundar,
**hui Wang,
Rishi Raj Goel,
YoSon Park,
the COVID-19 Review Consortium,
Simina M. Boca,
Anthony Gitter,
Casey S. Greene
Abstract:
After emerging in China in late 2019, the novel Severe acute respiratory syndrome-like coronavirus 2 (SARS-CoV-2) spread worldwide and as of early 2021, continues to significantly impact most countries. Only a small number of coronaviruses are known to infect humans, and only two are associated with the severe outcomes associated with SARS-CoV-2: Severe acute respiratory syndrome-related coronavir…
▽ More
After emerging in China in late 2019, the novel Severe acute respiratory syndrome-like coronavirus 2 (SARS-CoV-2) spread worldwide and as of early 2021, continues to significantly impact most countries. Only a small number of coronaviruses are known to infect humans, and only two are associated with the severe outcomes associated with SARS-CoV-2: Severe acute respiratory syndrome-related coronavirus, a closely related species of SARS-CoV-2 that emerged in 2002, and Middle East respiratory syndrome-related coronavirus, which emerged in 2012. Both of these previous epidemics were controlled fairly rapidly through public health measures, and no vaccines or robust therapeutic interventions were identified. However, previous insights into the immune response to coronaviruses gained during the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) have proved beneficial to identifying approaches to the treatment and prophylaxis of novel coronavirus disease 2019 (COVID-19). A number of potential therapeutics against SARS-CoV-2 and the resultant COVID-19 illness were rapidly identified, leading to a large number of clinical trials investigating a variety of possible therapeutic approaches being initiated early on in the pandemic. As a result, a small number of therapeutics have already been authorized by regulatory agencies such as the Food and Drug Administration (FDA) in the United States, and many other therapeutics remain under investigation. Here, we describe a range of approaches for the treatment of COVID-19, along with their proposed mechanisms of action and the current status of clinical investigation into each candidate. The status of these investigations will continue to evolve, and this review will be updated as progress is made.
△ Less
Submitted 10 September, 2021; v1 submitted 3 March, 2021;
originally announced March 2021.
